Recent News

BriaCell Receives FDA Authorization to Initiate Phase I/IIa Trial of Cell-Based Immunotherapy BriaVax(TM) in Advanced Breast Cancer Patients

BriaCell Therapeutics Corp. November 4, 2015 11:01 AM BERKELEY, CA and VANCOUVER, BC–(Marketwired – November 04, 2015) – BriaCell Therapeutics Corp (BCTXF) (TSX VENTURE: BCT) (“BriaCell”, the “Company”, or “BCT”) is pleased to announce that the U.S. Food and Drug Administration (FDA) has given final clearance for the Company’s Investigational New Drug (IND) application to […]